NAD Boosters: Evidence Versus Marketing

Human trials of the two most marketed NAD+ precursors, nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), point to one consistent finding: they raise NAD+ in the blood. What those trials have not shown is that the extra NAD+ makes anyone live longer or age more slowly. Every rigorous review of the human data lands in the same place. The molecules move a biomarker, and the healthspan and longevity claims stacked on top of that biomarker remain unproven.

Why NAD+ became a target

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme every cell uses for energy metabolism, DNA repair, and the activity of enzymes such as sirtuins and PARPs. Tissue NAD+ appears to fall with age in several organisms, and restoring it reverses some deficits in mice. That biology is genuinely interesting, and it is the honest basis for studying NR and NMN, both of which feed the salvage pathway that regenerates NAD+. The problem is not the hypothesis. It is the distance between the hypothesis and what has actually been measured in people.

The biomarker moves

The pharmacology holds up in humans. In a randomized, double-blind, placebo-controlled crossover trial published in Nature Communications, Martens and colleagues gave 24 healthy adults aged 55 to 79 either 1000 mg of NR daily or placebo for six weeks each. NR was well tolerated and raised NAD+ in peripheral blood cells by roughly 60 percent over placebo. That is a clean, reproducible pharmacodynamic result.

Look at the clinical endpoints in the same study and the picture changes. The authors reported no significant effect on exercise capacity, metabolic function, or motor performance. They did observe a hint of lower blood pressure and arterial stiffness in the subset with elevated baseline pressure, which they correctly framed as a hypothesis to test rather than a proven benefit.

NMN tells a similar story. A 2023 review in Advances in Nutrition by Song and colleagues pooled the published human NMN trials, which used doses from roughly 100 to 2000 mg daily in small groups, mostly older adults. Across those studies NMN was generally safe and raised blood NAD+ by about 1.7 to 2.7 fold. The signals for function were modest and inconsistent, such as improved insulin sensitivity in one group of prediabetic women, and NAD+ did not always rise in skeletal muscle even when it rose in blood. The reviewers' own conclusion is the fair summary of the field: clear evidence for antiaging effects in humans remains scarce, and it is too early to say NAD+ supplementation will delay age-related decline.

What "unproven" actually means here

The endpoints that would justify a longevity claim are hard ones: death, incident disease, loss of physical or cognitive function, disability. No NAD+ precursor has been shown to change any of them in a controlled human trial. The published studies are small, run for weeks to a few months, and report surrogate outcomes. A biomarker moving in the direction you hoped for is a reason to run the larger, longer trial, not a substitute for having run it. Marketing tends to treat the surrogate as the destination.

Research compound versus supplement

The regulatory history of these ingredients is a useful lens, and it is frequently misread. Under section 201(ff)(3)(B) of the Federal Food, Drug, and Cosmetic Act, an article approved as a new drug, or authorized for investigation as a new drug with substantial clinical trials made public, is generally excluded from the definition of a dietary supplement unless it was marketed as a supplement or food first. That single clause explains why two chemically related molecules can sit in different legal boxes.

NR entered the market through the supplement and food pathways. FDA reviewed it under new dietary ingredient notifications and issued a "no questions" response to a generally recognized as safe (GRAS) notice for nicotinamide riboside chloride as a source of vitamin B3. NMN followed a different path: it was authorized for investigation as a new drug, and in 2022 FDA took the position that this history excluded NMN from the supplement definition, a stance the agency later revised. The point for a reader is what these categories do and do not mean. Being studied as an investigational drug is not evidence that a compound works, and being sold lawfully as a supplement is not evidence either. Legal status describes a regulatory pathway, not a proven effect on aging.

Reading the marketing

A few patterns separate the science from the sales copy. Watch for mouse or cell data presented as if it were human proof, for the leap from "raises NAD+" to "reverses aging," and for the invocation of sirtuins and famous laboratories as if a mechanism were an outcome. Before-and-after biomarker charts show that a product does what its pharmacology predicts, which is a different claim from showing it helps you. Biological-age tests deserve particular skepticism as promotional props; they are research tools with real measurement noise, not individual verdicts on how fast you are aging.

The useful questions are simple. Is the endpoint a hard outcome or a surrogate? Was the study randomized and controlled, and how many people ran for how long? Who funded it? Applied honestly, those questions leave NR and NMN where the evidence puts them today: acceptable for short-term safety at studied doses, reliable at raising a biomarker, and unproven for the healthspan and longevity claims that sell them.

This article is educational and is not medical advice; decisions about supplements belong with a qualified clinician who knows your history.